Kidney disease in China: Recent progress and prospects

Chinese Medical Journal

Volumn 122, Issue 17, 2009, Pages 2048-2053

  Yu, Xue Qing ^a   Wei, Jia Li ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

China; Kidney disease; Progress

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ENALAPRIL; GLITAZONE DERIVATIVE; LEFLUNOMIDE; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIOGLITAZONE; PREDNISOLONE; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; ROSIGLITAZONE; STEROID; TACROLIMUS; VALSARTAN;

ANTIINFLAMMATORY ACTIVITY; ARISTOLOCHIC ACID NEPHROPATHY; CHINA; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG POTENTIATION; DRUG RESPONSE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DISEASE; KIDNEY TUBULE DISORDER; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; RENAL PROTECTION; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

CHINA; DIABETIC NEPHROPATHIES; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY DISEASES; LUPUS NEPHRITIS;

EID: 70350522198     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.17.016     Document Type: Review

References (58)

1. Miyata T, Nangaku M, Suzuki D, Inagi R, Uragami K, Sakai H, et al. A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy. J Clin Invest 1998; 102: 828-836. (Pubitemid 28399616)
2. Li YJ, Du Y, Li CX, Guo H, Leung JC, Lam MF, et al. Family-based association study showing that immunoglobulin A nephropathy is associated with the polymorphisms 2093C and 2180T in the 3′ untranslated region of the Megsin gene. J Am Soc Nephrol 2004; 15: 1739-1743. (Pubitemid 38822052)
3. Xu G, He Q, Shou Z, Wang H, Zhang X, Wang Y, et al. NA1/NA2 heterozygote of Fcgr3b is a risk factor for progression of IgA nephropathy in Chinese. J Clin Lab Anal 2007; 21: 298-302. (Pubitemid 47556809)
4. Li GS, Zhang H, Lü JC, Shen Y, Wang HY. Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int 2007; 71: 448-453. (Pubitemid 46303566)
5. Feng XZ, Hou P, Zhu L, Yu L, Zhang H. Correlation of TFRC polymorphism with the susceptibility and clinicpathologic phenotypes of IgA nephropathy. J Peking Univ Health Sci (Chin) 2008; 40: 369-373.
6. Leung JC, Chan LY, Tang SC, Tam PC, Fenn J, Lai KN. Glycosylation profile of differently charged IgA1 and their binding characteristics to cultured mesangial cells in IgA nephropathy. Nephron Exp Nephrol 2007; 107: e107-e118. (Pubitemid 350073620)
7. Gao YH, Xu LX, Zhang JJ, Zhang Y, Zhao MH, Wang HY. Differential binding characteristics of native monomeric and polymeric immunoglobulin A1 (IgA1) on human mesangial cells and the influence of in vitro deglycosylation of IgA1 molecules. Clin Exp Immunol 2007; 148: 507-514.
8. + B cells in primary IgA nephropathy. J Am Soc Nephrol 2008; 19: 2130-2139.
9. Wang C, Peng H, Tang H, Liu X, Chen Z, Lou T, et al. Serum IgA1 from IgA nephropathy patients induces apoptosis in podocytes through direct and indirect pathways. Clin Invest Med 2007; 30: E240-E249. (Pubitemid 350248524)
10. Tian J, Wang HP, Mao YY, Jin J, Chen JH. Reduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin A nephropathy. J Int Med Res 2007; 35: 338-345. (Pubitemid 46971354)
11. Li G, Zhang H, Lü J, Hou P, Wang H. Tandem repeats polymorphism of MUC20 is an independent factor for the progression of immunoglobulin A nephropathy. Am J Nephrol 2006; 26: 43-49.
12. Cao HX, Li M, Nie J, Wang W, Zhou SF, Yu XQ. Human leukocyte antigen DRB1 alleles predict risk and disease progression of immunoglobulin A nephropathy in Han Chinese. Am J Nephrol 2008; 28: 684-691. (Pubitemid 351832457)
13. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36: 227-237. (Pubitemid 30485830)
14. Lü J, Zhang H, Zhou Y, Li G, Zou W, Wang H. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China. Nephrology (Carlton) 2008; 13: 242-246. (Pubitemid 351341460)
15. Shen P, He L, Li Y, Wang Y, Chan M. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract 2007; 106: c157-c161. (Pubitemid 47172275)
16. Ding JX, Xu LX, Lü JC, Zhao MH, Zhang H, Wang HY. Aberrant sialylation of serum IgA1 was associated with prognosis of patients with IgA nephropathy. Clin Immunol 2007; 125: 268-274. (Pubitemid 350116717)
17. Wu J, Chen X, Xie Y, Yamanaka N, Shi S, Wu D, et al. Characteristics and risk factors of intrarenal arterial lesions in patients with IgA nephropathy. Nephrol Dial Transplant 2005; 20: 719-727. (Pubitemid 40520648)
18. Zhang JJ, Xu LX, Liu G, Zhao MH, Wang HY. The level of serum secretory IgA of patients with IgA nephropathy is elevated and associated with pathological phenotypes. Nephrol Dial Transplant 2008; 23: 207-212. (Pubitemid 351767351)
19. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
20. Tang Z, Yang G, Yu C, Yu Y, Wang J, Hu W, et al. Effects of mycophenolate mofetil for patients with crescentic lupus nephritis. Nephrology (Carlton) 2008; 13: 702-707.
21. Lu F, Tu Y, Peng X, Wang L, Wang H, Su Z, et al. MMF in induction therapy for active lupus nephritis in mainland China study group. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus 2008; 17: 622-629.
22. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008; 19: 2001-2010.
23. Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007; 16: 707-712. (Pubitemid 47517865)
24. Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007; 22: 1933-1942. (Pubitemid 47244763)
25. Haubitz M. Exploring new territory: the move towards individualised treatment. Lupus 2007; 16: 227-231. (Pubitemid 46506604)
26. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999; 58: 1137-1164. (Pubitemid 30055049)
27. Cui TG, Hou FF, Ni ZH, Chen XM, Zhang FS, Zhu TY, et al. Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multicenter controlled clinical trial. Chin J Intern Med (Chin) 2005; 44: 672-676.
28. Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 2008; 17: 638-644.
29. Zhang FS, Nie YK, Jin XM, Yu HM, Li YN, Sun Y. The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy. Rheumatol Int 2008; 25: Epub ahead of print.
30. Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother 2001; 2: 1903-1917.
31. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-340.
32. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007; 67: 369-391. (Pubitemid 46425551)
33. Lui SL, Tsang R, Chan KW, Zhang F, Tam S, Yung S, et al. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrol Dial Transplant 2008; 23: 2768-2776. (Pubitemid 351655798)
34. Boutayeb A, Boutayeb S. The burden of non communicable diseases in developing countries. Int J Equity Health 2005; 4: 2. (Pubitemid 40300842)
35. Wu YG, Lin H, Qi XM, Wu GZ, Qian H, Zhao M, et al. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. Int Immunopharmacol 2006; 6: 445-453. (Pubitemid 43120459)
36. Wu X, Zha D, Xiang G, Zhang B, Xiao SY, Jia R. Combined MMF and insulin therapy prevents renal injury in experimental diabetic rats. Cytokine 2006; 36: 229-236. (Pubitemid 46529474)
37. Zhang Y, Chen B, Hou XH, Guan GJ, Liu G, Liu HY, et al. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats. Chin Med J 2007; 120: 988-995. (Pubitemid 46902179)
38. Wu Y, Dong J, Yuan L, Liang C, Ren K, Zhang W, et al. Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy. Cytokine 2008; 44: 85-91.
39. Chen B, Zhang Y, Liu G, Guan GJ, Hou XH, Li XG, et al. Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats. Natl Med J Chin (Chin) 2008; 88: 540-545. (Pubitemid 351682031)
40. Wu YG, Lin H, Qian H, Zhao M, Qi XM, Wu GZ, et al. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats. Inflamm Res 2006; 55: 192-199. (Pubitemid 44035070)
41. Bao Y, Jia RH, Yuan J, Li J. Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacology 2007; 80: 57-64. (Pubitemid 47013368)
42. Yu X, Li C, Li X, Cai L. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1. Toxicol Sci 2007; 96: 346-356. (Pubitemid 46432031)
43. Dong FQ, Li H, Cai WM, Tao J, Li Q, Ruan Y, et al. Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin Med J 2004; 117: 1040-1044. (Pubitemid 39144892)
44. Jin HM, Pan Y. Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. Kidney Blood Press Res 2007; 30: 203-211. (Pubitemid 47076217)
45. Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007; 27: 495-502. (Pubitemid 47482007)
46. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341: 387-391. (Pubitemid 23048140)
47. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342: 1686-1692. (Pubitemid 30354515)
48. Nortier JL, Vanherweghem JL. Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). Toxicology 2002; 181-182: 577-580.
49. Wang Y, Zhang Z, Shen H, Lu Y, Li H, Ren X, et al. TGF-beta1/Smad7 signaling stimulates renal tubulointerstitial fibrosis induced by AAI. J Recept Signal Transduct Res 2008; 28: 413-428.
50. Qi X, Cai Y, Gong L, Liu L, Chen F, Xiao Y, et al. Role of mitochondrial permeability transition in human renal tubular epithelial cell death induced by aristolochic acid. Toxicol Appl Pharmacol 2007; 222: 105-110. (Pubitemid 46962657)
51. Wang HL, Zhang JY. Aristolochic acid induces renal tubular injury and inhibits expression of bone morphogenetic protein-7 mRNA in renal tissue of rats. J Chin Integr Med 2008; 6: 501-507.
52. Yang L, Li X, Wang H. Possible mechanisms explaining the tendency towards interstitial fibrosis in aristolochic acid-induced acute tubular necrosis. Nephrol Dial Transplant 2007; 22: 445-456. (Pubitemid 46189888)
53. Sun D, Feng J, Dai C, Sun L, Jin T, Ma J, et al. Role of peritubular capillary loss and hypoxia in progressive tubulointerstitial fibrosis in a rat model of aristolochic acid nephropathy. Am J Nephrol 2006; 26: 363-371. (Pubitemid 44394155)
54. Wen YJ, Qu L, Li XM. Ischemic injury underlies the pathogenesis of aristolochic acid-induced acute kidney injury. Transl Res 2008; 152: 38-46.
55. Wang W, Zhang J. Protective effect of erythropoietin against aristolochic acid-induced apoptosis in renal tubular epithelial cells. Eur J Pharmacol 2008; 588: 135-1340.
56. Zhu YF, Chen YP, Rui HL, Dong HR, Hu Z. Protective effects of Hirsutella sinensis on renal interstitial fibrosis: experiment with rat model of chronic aristolochic acid nephropathy. Natl Med J Chin (Chin) 2007; 87: 2667-2671. (Pubitemid 351148314)
57. Sun D, Feng JM, Zhao YL, Jin T, Wang LN. Effects of prostaglandin E1 on the progression of aristolochic acid nephropathy. Chin Med Sci J (Chin) 2005; 20: 67-69. (Pubitemid 40490885)
58. Xie Y, Chen X. Epidemiology, major outcomes, risk factors, prevention and management of chronic kidney disease in China. Am J Nephrol 2008; 28: 1-7. (Pubitemid 350126487)